[go: up one dir, main page]

SV2008002986A - Moduladores de indol sulfonamida de receptores de progesterona ref. x-17207 - Google Patents

Moduladores de indol sulfonamida de receptores de progesterona ref. x-17207

Info

Publication number
SV2008002986A
SV2008002986A SV2008002986A SV2008002986A SV2008002986A SV 2008002986 A SV2008002986 A SV 2008002986A SV 2008002986 A SV2008002986 A SV 2008002986A SV 2008002986 A SV2008002986 A SV 2008002986A SV 2008002986 A SV2008002986 A SV 2008002986A
Authority
SV
El Salvador
Prior art keywords
indol
ref
progesterone receptors
sulfonamide
modulators
Prior art date
Application number
SV2008002986A
Other languages
English (en)
Inventor
Thomas John Bleisch
Christian Alexander Clarke
Scott Alan Jones
Jeffrey Alan Dodge
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2008002986A publication Critical patent/SV2008002986A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA I: (VER FORMULA); EN DONDE N ES 1 O 2, Y R1, R2, R3, R4, R5, R6, R7 Y R8 SON COMO SE DEFINEN AQUI, SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS Y MÉTODOS DE USO
SV2008002986A 2006-01-24 2008-07-24 Moduladores de indol sulfonamida de receptores de progesterona ref. x-17207 SV2008002986A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76163706P 2006-01-24 2006-01-24

Publications (1)

Publication Number Publication Date
SV2008002986A true SV2008002986A (es) 2010-01-18

Family

ID=38180657

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2008002986A SV2008002986A (es) 2006-01-24 2008-07-24 Moduladores de indol sulfonamida de receptores de progesterona ref. x-17207

Country Status (30)

Country Link
US (1) US7932284B2 (es)
EP (1) EP1979314B1 (es)
JP (1) JP4912414B2 (es)
KR (1) KR101126895B1 (es)
CN (1) CN101374808B (es)
AR (1) AR059176A1 (es)
AU (1) AU2007208109B2 (es)
BR (1) BRPI0706411A2 (es)
CA (1) CA2637933C (es)
CR (1) CR10236A (es)
DK (1) DK1979314T3 (es)
DO (1) DOP2007000018A (es)
EA (1) EA014470B1 (es)
EC (1) ECSP088641A (es)
ES (1) ES2399112T3 (es)
HR (1) HRP20130058T1 (es)
IL (1) IL192021A (es)
MA (1) MA30207B1 (es)
MY (1) MY146494A (es)
NO (1) NO20083553L (es)
NZ (1) NZ568910A (es)
PE (1) PE20071245A1 (es)
PT (1) PT1979314E (es)
SI (1) SI1979314T1 (es)
SV (1) SV2008002986A (es)
TN (1) TNSN08311A1 (es)
TW (1) TWI368613B (es)
UA (1) UA94600C2 (es)
WO (1) WO2007087488A2 (es)
ZA (1) ZA200805757B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2011042473A2 (en) * 2009-10-07 2011-04-14 Karo Bio Ab Novel estrogen receptor ligands
JP2013536193A (ja) 2010-08-11 2013-09-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリール類およびその使用
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EA201390539A1 (ru) 2010-10-13 2013-09-30 Милленниум Фармасьютикалз, Инк. Гетероарилы и их применение
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
AR091731A1 (es) 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
TWI567059B (zh) 2014-05-15 2017-01-21 埃帝歐斯醫療公司 吡咯啶－２，５－二酮衍生物、醫藥組合物及用做為ｉｄｏ１抑制劑之方法
CN104529866A (zh) * 2014-12-12 2015-04-22 广东东阳光药业有限公司 吲哚类衍生物及其在药物上的应用
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
CN107635990A (zh) 2015-03-17 2018-01-26 辉瑞公司 新型3‑吲哚取代的衍生物、药物组合物及使用方法
WO2017025868A1 (en) 2015-08-10 2017-02-16 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
CN105906530A (zh) * 2016-04-27 2016-08-31 昆药集团股份有限公司 一种绿色环保的卤代芳基甲氰的制备方法
CN109414596B (zh) * 2016-05-12 2023-09-29 密歇根大学董事会 Ash1l抑制剂和用其进行治疗的方法
WO2019094772A1 (en) * 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l degraders and methods of treatment therewith
CA3245542A1 (en) 2022-03-23 2023-09-28 Ideaya Biosciences Inc Piperazine substitute indazole compounds used as paracetamol inhibitors
CN114903996B (zh) * 2022-06-22 2023-10-20 武汉大学中南医院 Hedgehog通路的特异性抑制剂在制备用于治疗宫腔粘连的药物中的应用
KR20250097400A (ko) * 2023-12-21 2025-06-30 한미약품 주식회사 Yap-tead 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
ATE264318T1 (de) * 1996-11-19 2004-04-15 Amgen Inc Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
DE19749453A1 (de) 1997-11-10 1999-05-12 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte anellierte 5-Ring-Verbindungen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
SK12752000A3 (sk) 1998-02-25 2001-03-12 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
US6417214B1 (en) * 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
AU2002362603A1 (en) * 2001-09-26 2003-04-07 Bayer Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
ES2187300B1 (es) 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
US7247333B2 (en) * 2003-03-19 2007-07-24 Pepsico Inc. Stabilized milk product containing fruit and fruit juice
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
BR0313923A (pt) 2002-08-29 2005-07-12 Boehringer Ingelheim Pharma Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
AU2004237420B2 (en) 2003-05-09 2009-04-09 Laboratorios Del Dr. Esteve S.A. Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
ES2222832B1 (es) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
EP1689389A4 (en) 2003-12-04 2009-06-17 Nat Health Research Institutes INDOLE COMPOUNDS
US7728150B2 (en) 2004-03-03 2010-06-01 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
CN1980917B (zh) 2004-05-03 2014-02-12 詹森药业有限公司 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物
PL1809602T3 (pl) 2004-10-27 2009-04-30 Janssen Pharmaceutica Nv Pochodne indolowe przydatne jako modulatory receptora progesteronu

Also Published As

Publication number Publication date
ECSP088641A (es) 2008-08-29
AU2007208109A1 (en) 2007-08-02
KR101126895B1 (ko) 2012-03-20
PE20071245A1 (es) 2008-01-30
AR059176A1 (es) 2008-03-12
ES2399112T3 (es) 2013-03-25
JP2009526762A (ja) 2009-07-23
TWI368613B (en) 2012-07-21
CR10236A (es) 2008-11-28
UA94600C2 (en) 2011-05-25
DK1979314T3 (da) 2013-02-04
CN101374808B (zh) 2011-05-25
CN101374808A (zh) 2009-02-25
US20090069400A1 (en) 2009-03-12
EP1979314A2 (en) 2008-10-15
MA30207B1 (fr) 2009-02-02
HK1124328A1 (en) 2009-07-10
NZ568910A (en) 2011-04-29
NO20083553L (no) 2008-10-20
DOP2007000018A (es) 2007-08-31
WO2007087488A3 (en) 2007-09-13
BRPI0706411A2 (pt) 2011-03-29
TNSN08311A1 (en) 2009-12-29
MY146494A (en) 2012-08-15
KR20080088609A (ko) 2008-10-02
EA200870196A1 (ru) 2009-02-27
US7932284B2 (en) 2011-04-26
IL192021A0 (en) 2008-12-29
EP1979314B1 (en) 2013-01-09
IL192021A (en) 2013-02-28
JP4912414B2 (ja) 2012-04-11
CA2637933C (en) 2013-03-12
TW200738631A (en) 2007-10-16
HRP20130058T1 (hr) 2013-02-28
CA2637933A1 (en) 2007-08-02
AU2007208109B2 (en) 2012-08-23
ZA200805757B (en) 2009-11-25
SI1979314T1 (sl) 2013-02-28
WO2007087488A9 (en) 2008-08-28
EA014470B1 (ru) 2010-12-30
PT1979314E (pt) 2013-03-05
WO2007087488A2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
SV2008002986A (es) Moduladores de indol sulfonamida de receptores de progesterona ref. x-17207
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
CR11861A (es) Compuestos organicos
BRPI0411528A (pt) uso de isomalte como prebiótico
MA34078B1 (fr) Derives d'arylethynyle
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
SV2011003800A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CL2012001072A1 (es) Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas.
PA8781701A1 (es) Derivados de 7-alquinil-1,8- naftiridonas, su preparaciones y su aplicacion en terapeutica
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
EA200601895A1 (ru) 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
EA201001842A1 (ru) Новые соединения, обладающие активностью антагонистов мускариновых рецепторов
ECSP099679A (es) Nuevos compuestos y sus usos 707
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
ATE546448T1 (de) Urotensin-ii-rezeptorantagonisten
ATE525360T1 (de) Neuartige imidazolinylmethyl-aryl-sulfonamide
CO6541615A2 (es) Tiazoles bicíclicos como moduladores alostéricos de receptores mglur5